Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J W Sander

Showing results (31-40 of 206) with videos related to

Pageof 21
Sort By:
Revue Neurologique|January 1, 1997
How rational is current anti-epileptic drug treatment?M F O'Donoghue, J W Sander
Neurology|August 1, 1997
Difficulties in extrapolating from clinical trial data to clinical practice: the case of antiepileptic drugsM C Walker, J W Sander
Journal of Neurology, Neurosurgery, and Psychiatry|October 1, 1991
The Chalfont Seizure Severity ScaleJ S Duncan, J W Sander
Acta Neurologica Scandinavica. Supplementum|November 9, 2011
Vigabatrin therapy for refractory complex partial seizures: review of major European trialsE Ben-Menachem, J W Sander
Current Opinion in Neurology|April 1, 1994
Developments in antiepileptic drug therapyM C Walker, J W Sander
Epilepsia|November 14, 2009
The mortality associated with epilepsy, with particular reference to sudden unexpected death: a reviewM F O'Donoghue, J W Sander
The Journal of the Royal College of General Practitioners|February 1, 1988
Epilepsy in the communityJ W Sander, S D Shorvon
Current Pharmaceutical Design|June 1, 2000
Stopping drug therapy in epilepsyS D Lhatoo, J W Sander
Journal of Neurology, Neurosurgery, and Psychiatry|March 20, 2001
The clinical impact of epilepsy geneticsM R Johnson, J W Sander
BMJ (Clinical Research Ed.)|January 5, 1999
Infantile spasms and vigabatrin. Visual field defects may be permanentS D Lhatoo, J W Sander
Pageof 21

Showing results (31-40 of 206) with videos related to

Sort By:
Pageof 21
Revue Neurologique|January 1, 1997
How rational is current anti-epileptic drug treatment?M F O'Donoghue, J W Sander
Neurology|August 1, 1997
Difficulties in extrapolating from clinical trial data to clinical practice: the case of antiepileptic drugsM C Walker, J W Sander
Journal of Neurology, Neurosurgery, and Psychiatry|October 1, 1991
The Chalfont Seizure Severity ScaleJ S Duncan, J W Sander
Acta Neurologica Scandinavica. Supplementum|November 9, 2011
Vigabatrin therapy for refractory complex partial seizures: review of major European trialsE Ben-Menachem, J W Sander
Current Opinion in Neurology|April 1, 1994
Developments in antiepileptic drug therapyM C Walker, J W Sander
Epilepsia|November 14, 2009
The mortality associated with epilepsy, with particular reference to sudden unexpected death: a reviewM F O'Donoghue, J W Sander
The Journal of the Royal College of General Practitioners|February 1, 1988
Epilepsy in the communityJ W Sander, S D Shorvon
Current Pharmaceutical Design|June 1, 2000
Stopping drug therapy in epilepsyS D Lhatoo, J W Sander
Journal of Neurology, Neurosurgery, and Psychiatry|March 20, 2001
The clinical impact of epilepsy geneticsM R Johnson, J W Sander
BMJ (Clinical Research Ed.)|January 5, 1999
Infantile spasms and vigabatrin. Visual field defects may be permanentS D Lhatoo, J W Sander
Pageof 21